Tonix Pharmaceuticals stock halted ahead of FDA approval news
Laurie Ann Pulatie-Hahn, SVP, HR at Itron, Inc. (NASDAQ:ITRI), a $5.7 billion market cap company whose stock has surged nearly 27% over the past six months according to InvestingPro, sold 78 shares of common stock on August 11, 2025, at a price of $124.6465, for a total of $9722.
The sale was disclosed in a Form 4 filing with the Securities and Exchange Commission. Following the transaction, Pulatie-Hahn directly owns 22219 shares of Itron, Inc.
The shares sold were to cover tax withholding obligations associated with the vesting of a restricted stock unit award.
In other recent news, Itron reported its second-quarter 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.62, compared to the forecasted $1.32. However, the company’s revenue slightly missed projections, totaling $607 million against an expected $609 million. Despite the earnings beat, investor concerns about revenue led to a negative market reaction. Analysts have responded to Itron’s financial performance with adjustments in stock ratings and price targets. JPMorgan upgraded Itron to Overweight from Neutral, raising its price target to $145, citing strong margins as a key factor. Stephens also increased its price target for Itron to $130 while maintaining an Equal Weight rating. Both firms noted the company’s record margins, despite lower sales guidance. Additionally, Itron’s bookings grew by 2% year-over-year, maintaining a book-to-bill ratio of 0.75x.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.